Navigation Links
Adipose stem cell heart attack trial data published in JACC
Date:1/24/2012

San Diego Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of previously reported six-month outcomes from APOLLO, the Company's European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction (heart attack or AMI), as Research Correspondence in the Journal of the American College of Cardiology. The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA) evaluating autologous ADRCs extracted with the Company's proprietary Celution System for the treatment of patients suffering from acute myocardial infarction.

In the APOLLO trial all patients were treated with standard-of-care and subsequently underwent an abdominal liposuction. Each patient's adipose tissue was processed by the Celution System where ADRCs were extracted, washed and concentrated into a syringe of clinical grade cells. Within 36 hours of the myocardial infarction and no longer than 24 hours after undergoing percutaneous coronary intervention, patients received an injection of either 20 million ADRCs (n=10) or a placebo (n=4).

The publication reported:

  • Safety
    • The procedure could be safely performed in an acute setting
    • No side effects from ADRC delivery, processed using Celution
    • No increase in arrhythmias
  • Feasibility
    • Improvement in cardiac function by SPECT
    • Improvement in blood flow into the heart muscle (perfusion defect)
    • Reduction in scar formation (infarct size)

"Based on both the six and 18-month outcomes, which showed continued safety and sustained long-term benefits, we initiated ADVANCE, a pivotal, prospective, randomized, double-blind, European heart attack trial in up to 360 patients," said Christopher J. Calhoun, CEO for Cytori. "The goal of our ADRC therapy is to reduce scarring, preserve heart muscle beyond what can be salvaged with current treatments, minimize harmful remodeling, and ultimately protect patients from advancing into heart failure."

The publication, co-authored by trial investigators Drs. Henricus J. Duckers, Patrick W. Serruys, Jaco H. Houtgraaf at Thoraxcenter, Erasmus University Hospital and others, reported the following:

  • The percentage of left ventricle (LV) infarcted was reduced by 52% (31.6 5.3% to 15.3 2.6% at six-month follow-up, p=0.002) in the ADRC-treated patients, as opposed to no change in the placebo-treated AMI patients (24.7 9.2 % vs. 24.7 4.1%). The difference between the groups was not statistically significant.

  • There was a significant improvement of the perfusion defect in ADRC-treated patients from 16.9 2.1% to 10.9 2.4% at six-month follow-up (change of 6.0%, p=0.004) as compared to a deterioration in the placebo group by 1.8% (15.0 4.9% to 16.8 4.3%).

  • Left ventricular ejection fraction (LVEF), measured by SPECT, improved with an absolute difference of +5.7% (p=0.114). In ADRC treated patients, LVEF improved by 4% (52.1% to 56.1%), as compared to a deterioration of 1.7% in the placebo group (52.0% to 50.3%).

"The advantage of adipose tissue as a cell source is that it allows physicians to get a meaningful dose of a patient's own cells at the point-of-care when using the Celution System without cell culture or use of donor cells," said Dr. Duckers, lead author of the paper. "We believe delivering cells within the first 24 to 36 hours takes advantage of the body's signaling and initiates the repair process before irreparable damage occurs."

Cytori is currently preparing the full 18 month data set for publication.


'/>"/>

Contact: Megan McCormick
mmccormick@cytori.com
858-875-5279
Cytori Therapeutics
Source:Eurekalert

Related biology news :

1. Fish oil during pregnancy does not protect against excessive adipose tissue development
2. The amount of adipose tissue should be taken into account in the fight against obesity
3. Cytori reports benefit of adipose-derived regenerative cells in spinal disc model
4. Hearty bacteria help make case for life in the extreme
5. The microbiome and disease: Gut bacteria influence the severity of heart attacks in rats
6. Viagra against heart failure: Researchers at the RUB and from Rochester throw light on the mechanism
7. New scanning strategy could help develop heart disease treatments
8. New Columbia engineering technique diagnoses non-periodic arrhythmias in a single heartbeat
9. Environment and diet leave their prints on the heart
10. Restricted calorie diet improves heart function in obese patients with diabetes
11. New design for mechanical heart valves
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
Breaking Biology Technology: